Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Breast Cancer

  Free Subscription

Articles published in Oncol Rep

Retrieve available abstracts of 168 articles:
HTML format

Single Articles

    November 2020
  1. JIN H, Choi H, Kim ES, Lee HH, et al
    Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinasetype plasminogen activator.
    Oncol Rep. 2020 Nov 6. doi: 10.3892/or.2020.7840.
    PubMed     Abstract available

  2. INAGAKI Y, Wu D, Fujiwara K, Ishizuka Y, et al
    Knockdown of E2F5 induces cell death via the TP53dependent pathway in breast cancer cells carrying wildtype TP53.
    Oncol Rep. 2020;44:2241-2252.
    PubMed     Abstract available

  3. ZHANG Q, Lei L, Jing D
    Knockdown of SERPINE1 reverses resistance of triplenegative breast cancer to paclitaxel via suppression of VEGFA.
    Oncol Rep. 2020;44:1875-1884.
    PubMed     Abstract available

  4. YANG B, Shi J, Sun Z, Zhu D, et al
    Attenuated measles virus overcomes radio and chemoresistance in human breast cancer cells by inhibiting the nonhomologous end joining pathway.
    Oncol Rep. 2020;44:2253-2264.
    PubMed     Abstract available

    October 2020
  5. HUANG T, Luo X, Wu B, Peng P, et al
    Pyrotinib enhances the radiosensitivity of HER2overexpressing gastric and breast cancer cells.
    Oncol Rep. 2020 Oct 21. doi: 10.3892/or.2020.7820.
    PubMed     Abstract available

  6. ALHAMMAD R, Khunchai S, Tongmuang N, Limjindaporn T, et al
    Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state.
    Oncol Rep. 2020 Oct 20. doi: 10.3892/or.2020.7816.
    PubMed     Abstract available

  7. XU L, Qu JL, Song N, Zhang LY, et al
    Biological and clinical significance of flap endonuclease1 in triplenegative breast cancer: Support of metastasis and a poor prognosis.
    Oncol Rep. 2020 Oct 16. doi: 10.3892/or.2020.7812.
    PubMed     Abstract available

  8. ZHANG M, Xiang Z, Wang F, Shan R, et al
    STARD4 promotes breast cancer cell malignancy.
    Oncol Rep. 2020 Oct 12. doi: 10.3892/or.2020.7802.
    PubMed     Abstract available

  9. SILVA-CAZARES MB, Saavedra-Leos MZ, Jordan-Alejandre E, Nunez-Olvera SI, et al
    Lipidbased nanoparticles for the therapeutic delivery of noncoding RNAs in breast cancer (Review).
    Oncol Rep. 2020 Oct 5. doi: 10.3892/or.2020.7791.
    PubMed     Abstract available

    September 2020
  10. LIU QQ, Huo HY, Ao S, Liu T, et al
    TGFbeta1induced epithelialmesenchymal transition increases fatty acid oxidation and OXPHOS activity via the pAMPK pathway in breast cancer cells.
    Oncol Rep. 2020;44:1206-1215.
    PubMed     Abstract available

  11. ZOU L, Imani S, Maghsoudloo M, Shasaltaneh MD, et al
    Genomewide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis.
    Oncol Rep. 2020;44:1075-1093.
    PubMed     Abstract available

    August 2020
  12. YANG Z, Liu Z, Chang Z, Yan G, et al
    MicroRNA1885p inhibits the progression of breast cancer by targeting zinc finger protein 91.
    Oncol Rep. 2020 Aug 12. doi: 10.3892/or.2020.7731.
    PubMed     Abstract available

  13. MENG L, Yue X, Zhou D, Li H, et al
    Long non coding RNA OIP5AS1 promotes metastasis of breast cancer via miR3405p/ZEB2 axis.
    Oncol Rep. 2020 Aug 10. doi: 10.3892/or.2020.7724.
    PubMed     Abstract available

  14. HU Q, Yuan Y, Wu Y, Huang Y, et al
    MicroRNA137 exerts protective effects on hypoxiainduced cell injury by inhibiting autophagy/mitophagy and maintaining mitochondrial function in breast cancer stemlike cells.
    Oncol Rep. 2020 Aug 3. doi: 10.3892/or.2020.7714.
    PubMed     Abstract available

  15. LI QH, Liu ZZ, Ge YNu, Liu X, et al
    Small breast epithelial mucin promotes the invasion and metastasis of breast cancer cells via promoting epithelialtomesenchymal transition.
    Oncol Rep. 2020;44:509-518.
    PubMed     Abstract available

  16. WANG L, Wang B, Wen H, Mao J, et al
    Exosomes: A rising star in breast cancer (Review).
    Oncol Rep. 2020;44:407-423.
    PubMed     Abstract available

    July 2020
  17. LI W, Sang M, Hao X, Wu Y, et al
    CTLA4 blockade combined with 5aza2'deoxycytidine enhances the killing effect of MAGEA family common antigen peptidespecific cytotoxic T cells on breast cancer.
    Oncol Rep. 2020 Jul 21. doi: 10.3892/or.2020.7701.
    PubMed     Abstract available

  18. YU Y, He Y, Shao Y, Chen Q, et al
    lncRNA PCNAP1 predicts poor prognosis in breast cancer and promotes cancer metastasis via miR3405pdependent upregulation of SOX4.
    Oncol Rep. 2020 Jul 20. doi: 10.3892/or.2020.7699.
    PubMed     Abstract available

  19. ZHANG H, Wei N, Zhang W, Shen L, et al
    lncRNA SNHG3 promotes breast cancer progression by acting as a miR326 sponge.
    Oncol Rep. 2020 Jul 15. doi: 10.3892/or.2020.7690.
    PubMed     Abstract available

    June 2020
  20. LI C, Li X, Li G, Sun L, et al
    Identification of a prognosisassociated signature associated with energy metabolism in triplenegative breast cancer.
    Oncol Rep. 2020 Jun 23. doi: 10.3892/or.2020.7657.
    PubMed     Abstract available

  21. SHI Y, Wang M, Wang P, Zhang T, et al
    Alisol A is potentially therapeutic in human breast cancer cells.
    Oncol Rep. 2020 Jun 22. doi: 10.3892/or.2020.7654.
    PubMed     Abstract available

  22. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    [Corrigendum] Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2020 Jun 19. doi: 10.3892/or.2020.7653.
    PubMed     Abstract available

  23. ZHAO S, Li X, Yin L, Hou L, et al
    TCRP1 induces tamoxifen resistance by promoting the activation of SGK1 in MCF7 cells.
    Oncol Rep. 2020;43:2017-2027.
    PubMed     Abstract available

    April 2020
  24. SONG Y, He L, Wang Y, Wu Q, et al
    Molecularly targeted therapy and immunotherapy for hormone receptorpositive/human epidermal growth factor receptor 2negative advanced breast cancer (Review).
    Oncol Rep. 2020 Apr 21. doi: 10.3892/or.2020.7589.
    PubMed     Abstract available

  25. CHEN L, Zhang S, Shen Y, Qi L, et al
    Thymusexpressed chemokine secreted by breast cancer cells promotes metastasis and inhibits apoptosis.
    Oncol Rep. 2020 Apr 3. doi: 10.3892/or.2020.7575.
    PubMed     Abstract available

    March 2020
  26. ZUO Y, Xu H, Chen Z, Xiong F, et al
    17AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDAMB231 breast cancer cells.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7563.
    PubMed     Abstract available

  27. DING Y, Ma M, Li Q, Gao S, et al
    Clinical significance of sHER2ECD and calpain10 expression in tumor tissues of patients with breast cancer.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7564.
    PubMed     Abstract available

  28. GAO X, Bao H, Liu L, Zhu W, et al
    Systematic analysis of lysine acetylome and succinylome reveals the correlation between modification of H2A.X complexes and DNA damage response in breast cancer.
    Oncol Rep. 2020 Mar 19. doi: 10.3892/or.2020.7554.
    PubMed     Abstract available

  29. HAN R, Zhao J, Lu L
    MicroRNA34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression.
    Oncol Rep. 2020 Mar 18. doi: 10.3892/or.2020.7549.
    PubMed     Abstract available

  30. SEGURA-BAUTISTA D, Olivares A, Casas-Gonzalez P, Bonilla E, et al
    GPR30 expression and function in breast cancer cells are induced through a cisacting element targeted by ETS factors.
    Oncol Rep. 2020 Mar 10. doi: 10.3892/or.2020.7540.
    PubMed     Abstract available

  31. XIONG X, Feng Y, Li L, Yao J, et al
    Long noncoding RNA SNHG1 promotes breast cancer progression by regulation of LMO4.
    Oncol Rep. 2020 Mar 4. doi: 10.3892/or.2020.7530.
    PubMed     Abstract available

    February 2020
  32. YI D, Wang R, Shi X, Xu L, et al
    METTL14 promotes the migration and invasion of breast cancer cells by modulating N6methyladenosine and hsamiR146a5p expression.
    Oncol Rep. 2020 Feb 24. doi: 10.3892/or.2020.7515.
    PubMed     Abstract available

    January 2020
  33. LI C, Wang A, Chen Y, Liu Y, et al
    MicroRNA2995p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39.
    Oncol Rep. 2020 Jan 31. doi: 10.3892/or.2020.7486.
    PubMed     Abstract available

  34. AL-YOUSEF N, Shinwari Z, Al-Shahrani B, Al-Showimi M, et al
    Curcumin induces reexpression of BRCA1 and suppression of gamma synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Oncol Rep. 2020 Jan 20. doi: 10.3892/or.2020.7473.
    PubMed     Abstract available

  35. ZHANG Z, Li Z, Deng M, Liu B, et al
    Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer.
    Oncol Rep. 2020 Jan 17. doi: 10.3892/or.2020.7471.
    PubMed     Abstract available

  36. DUAN Z, Andrews NP, Chen CZ, Fan M, et al
    Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNAdamaging chemotherapy agents and radiation.
    Oncol Rep. 2020;43:318-327.
    PubMed     Abstract available

    December 2019
  37. SHEVCHENKO JA, Khristin AA, Kurilin VV, Kuznetsova MS, et al
    Autologous dendritic cells and activated cytotoxic Tcells as combination therapy for breast cancer.
    Oncol Rep. 2019 Dec 16. doi: 10.3892/or.2019.7435.
    PubMed     Abstract available

  38. JUNG KH, Lee JH, Park JW, Moon SH, et al
    Troglitazone exerts metabolic and antitumor effects on T47D breast cancer cells by suppressing mitochondrial pyruvate availability.
    Oncol Rep. 2019 Dec 16. doi: 10.3892/or.2019.7436.
    PubMed     Abstract available

  39. ZHAO C, Zheng S, Yan Z, Deng Z, et al
    CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2.
    Oncol Rep. 2019 Dec 11. doi: 10.3892/or.2019.7426.
    PubMed     Abstract available

    November 2019
  40. WU H, Wang Q, Zhong H, Li L, et al
    Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by nextgeneration sequencing.
    Oncol Rep. 2019 Nov 6. doi: 10.3892/or.2019.7401.
    PubMed     Abstract available

  41. TRIVIZAKIS E, Ioannidis GS, Melissianos VD, Papadakis GZ, et al
    A novel deep learning architecture outperforming 'offtheshelf' transfer learning and featurebased methods in the automated assessment of mammographic breast density.
    Oncol Rep. 2019;42:2009-2015.
    PubMed     Abstract available

    October 2019
  42. QIN B, Zhao K, Wei J, Wang X, et al
    Novel evidence indicates the presence and replication of hepatitis B virus in breast cancer tissue.
    Oncol Rep. 2019 Oct 30. doi: 10.3892/or.2019.7393.
    PubMed     Abstract available

  43. CUI Y, Fan Y, Zhao G, Zhang Q, et al
    Novel lncRNA PSMG3AS1 functions as a miR1433p sponge to increase the proliferation and migration of breast cancer cells.
    Oncol Rep. 2019 Oct 25. doi: 10.3892/or.2019.7390.
    PubMed     Abstract available

  44. WANG JJ, Huang YQ, Song W, Li YF, et al
    Comprehensive analysis of the lncRNAassociated competing endogenous RNA network in breast cancer.
    Oncol Rep. 2019 Oct 15. doi: 10.3892/or.2019.7374.
    PubMed     Abstract available

  45. XIAO S, Zhu H, Luo J, Wu Z, et al
    miR4255p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN.
    Oncol Rep. 2019 Oct 14. doi: 10.3892/or.2019.7371.
    PubMed     Abstract available

  46. ABE M, Kagara N, Miyake T, Tanei T, et al
    Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation.
    Oncol Rep. 2019 Oct 10. doi: 10.3892/or.2019.7363.
    PubMed     Abstract available

  47. NAOI Y, Saito Y, Kishi K, Shimoda M, et al
    Development of recurrence risk score using 95gene classifier and its application to formalinfixed paraffinembedded tissues in ERpositive, HER2negative and nodenegative breast cancer.
    Oncol Rep. 2019 Oct 7. doi: 10.3892/or.2019.7358.
    PubMed     Abstract available

  48. AN G, Wu F, Huang S, Feng L, et al
    Effects of CCL5 on the biological behavior of breast cancer and the mechanisms of its interaction with tumorassociated macrophages.
    Oncol Rep. 2019 Oct 1. doi: 10.3892/or.2019.7344.
    PubMed     Abstract available

    September 2019
  49. DAI X, Chen X, Hakizimana O, Mei Y, et al
    Genetic interactions between ANLN and KDR are prognostic for breast cancer survival.
    Oncol Rep. 2019 Sep 24. doi: 10.3892/or.2019.7332.
    PubMed     Abstract available

  50. HUO H, Ye X, Yang H, Li Q, et al
    RSK4 inhibits breast cancer cell proliferation and invasion in vitro, and is correlated with estrogen receptor upregulation in breast cancer.
    Oncol Rep. 2019 Sep 20. doi: 10.3892/or.2019.7328.
    PubMed     Abstract available

    August 2019
  51. CHEN P, Feng Y, Zhang H, Shi X, et al
    MicroRNA192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1.
    Oncol Rep. 2019 Aug 30. doi: 10.3892/or.2019.7298.
    PubMed     Abstract available

  52. ZHANG W, Xu J, Wang K, Tang X, et al
    miR1393p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A.
    Oncol Rep. 2019 Aug 29. doi: 10.3892/or.2019.7297.
    PubMed     Abstract available

  53. WANG Z, Zhang M, Shan R, Wang YJ, et al
    MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells.
    Oncol Rep. 2019 Aug 23. doi: 10.3892/or.2019.7292.
    PubMed     Abstract available

  54. SUN Q, Fu Q, Li S, Li J, et al
    Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt/betacatenin signaling.
    Oncol Rep. 2019 Aug 22. doi: 10.3892/or.2019.7290.
    PubMed     Abstract available

  55. PAN H, Zheng Y, Pan Q, Chen H, et al
    Expression of LXRbeta, ABCA1 and ABCG1 in human triplenegative breast cancer tissues.
    Oncol Rep. 2019 Aug 14. doi: 10.3892/or.2019.7279.
    PubMed     Abstract available

  56. KATSUTA E, Maawy AA, Yan L, Takabe K, et al
    High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptorpositive breast cancer.
    Oncol Rep. 2019 Aug 12. doi: 10.3892/or.2019.7275.
    PubMed     Abstract available

  57. GORNOWICZ A, Szymanowski W, Bielawska A, Szymanowska A, et al
    Monoclonal antiMUC1 antibody with novel octahydropyrazino[2,1a:5,4a']diisoquinoline derivative as a potential multitargeted strategy in MCF7 breast cancer cells.
    Oncol Rep. 2019 Aug 2. doi: 10.3892/or.2019.7256.
    PubMed     Abstract available

    July 2019
  58. FAN C, Liu N, Fan S, Yang Z, et al
    Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform.
    Oncol Rep. 2019 Jul 30. doi: 10.3892/or.2019.7253.
    PubMed     Abstract available

  59. HONG Z, Hong C, Ma B, Wang Q, et al
    MicroRNA1263p inhibits the proliferation, migration, invasion, and angiogenesis of triplenegative breast cancer cells by targeting RGS3.
    Oncol Rep. 2019 Jul 26. doi: 10.3892/or.2019.7251.
    PubMed     Abstract available

  60. ZADA S, Hwang JS, Ahmed M, Lai TH, et al
    Protein kinase A activation by betaLapachone is associated with apoptotic cell death in NQO1overexpressing breast cancer cells.
    Oncol Rep. 2019 Jul 19. doi: 10.3892/or.2019.7243.
    PubMed     Abstract available

  61. WANG Y, Wang Y, Wang N, You L, et al
    Poly(ADPribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
    Oncol Rep. 2019 Jul 18. doi: 10.3892/or.2019.7242.
    PubMed     Abstract available

  62. KONGSEMA M, Wongkhieo S, Khongkow M, Lam EW, et al
    Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
    Oncol Rep. 2019 Jul 8. doi: 10.3892/or.2019.7225.
    PubMed     Abstract available

    June 2019
  63. DING W, Li D, Zhang P, Shi L, et al
    Mutual editing of alternative splicing between breast cancer cells and macrophages.
    Oncol Rep. 2019 Jun 18. doi: 10.3892/or.2019.7200.
    PubMed     Abstract available

  64. YU H, Yang C, Jian L, Guo S, et al
    Sulfasalazineinduced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor.
    Oncol Rep. 2019 Jun 6. doi: 10.3892/or.2019.7189.
    PubMed     Abstract available

  65. KAKIZAWA N, Suzuki K, Abe I, Endo Y, et al
    High relative levels of satellite alpha transcripts predict increased risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer and lacking BRCArelated clinical features.
    Oncol Rep. 2019 Jun 3. doi: 10.3892/or.2019.7182.
    PubMed     Abstract available

    May 2019
  66. MESSEHA SS, Zarmouh NO, Mendonca P, Alwagdani H, et al
    Effects of gossypol on apoptosisrelated gene expression in racially distinct triplenegative breast cancer cells.
    Oncol Rep. 2019 May 31. doi: 10.3892/or.2019.7179.
    PubMed     Abstract available

  67. WU M, Sun Q, Mo CH, Pang JS, et al
    Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.
    Oncol Rep. 2019 May 3. doi: 10.3892/or.2019.7147.
    PubMed     Abstract available

    April 2019
  68. HORGAN XJ, Tatum H, Brannan E, Paull DH, et al
    Resveratrol analogues surprisingly effective against triplenegative breast cancer, independent of ERalpha.
    Oncol Rep. 2019 Apr 16. doi: 10.3892/or.2019.7122.
    PubMed     Abstract available

  69. CHENG Z, Wei W, Wu Z, Wang J, et al
    ARPC2 promotes breast cancer proliferation and metastasis.
    Oncol Rep. 2019 Apr 12. doi: 10.3892/or.2019.7113.
    PubMed     Abstract available

  70. GARCIA-GARCIA F, Salinas-Vera YM, Garcia-Vazquez R, Marchat LA, et al
    miR1455p is associated with pathological complete response to neoadjuvant chemotherapy and impairs cell proliferation by targeting TGFbetaR2 in breast cancer.
    Oncol Rep. 2019 Apr 5. doi: 10.3892/or.2019.7102.
    PubMed     Abstract available

  71. FAN C, Liu N
    Identification of dysregulated microRNAs associated with diagnosis and prognosis in triplenegative breast cancer: An in silico study.
    Oncol Rep. 2019 Apr 2. doi: 10.3892/or.2019.7094.
    PubMed     Abstract available

    March 2019
  72. CHEN S, Li YQ, Yin XZ, Li SZ, et al
    Recombinant adenoviruses expressing apoptin suppress the growth of MCF7 breast cancer cells and affect cell autophagy.
    Oncol Rep. 2019 Mar 18. doi: 10.3892/or.2019.7077.
    PubMed     Abstract available

  73. SHI R, Wang C, Fu N, Liu L, et al
    Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
    Oncol Rep. 2019 Mar 15. doi: 10.3892/or.2019.7069.
    PubMed     Abstract available

  74. XIE Q, Wang S, Zhao Y, Zhang Z, et al
    MicroRNA-216a suppresses the proliferation and migration of human breast cancer cells via the Wnt/beta-catenin signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7050.
    PubMed     Abstract available

  75. LU S, Du Y, Cui F, Feng X, et al
    Downregulation of BAG1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Oncol Rep. 2019;41:1901-1910.
    PubMed     Abstract available

  76. ZHANG M, Liu Q, Li L, Ning J, et al
    Cytoplasmic MCSF facilitates apoptosis resistance by inhibiting the HIF1alpha/BNIP3/Bax signalling pathway in MCF7 cells.
    Oncol Rep. 2019;41:1807-1816.
    PubMed     Abstract available

    February 2019
  77. CHEN Y, He Y, Wang X, Lu F, et al
    Adiposederived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells.
    Oncol Rep. 2019 Feb 15. doi: 10.3892/or.2019.7018.
    PubMed     Abstract available

  78. DAI X, Geng F, Li M, Liu M, et al
    Tripartite motifcontaining 11 regulates the proliferation and apoptosis of breast cancer cells.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7015.
    PubMed     Abstract available

  79. JAERAPONG N, Jamil QA, Riha J, Milovanovic D, et al
    Organic aniontransporting polypeptides contribute to the uptake of curcumin and its main metabolites by human breast cancer cells: Impact on antitumor activity.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7011.
    PubMed     Abstract available

  80. GUTTLER A, Theuerkorn K, Riemann A, Wichmann H, et al
    Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
    Oncol Rep. 2019 Feb 5. doi: 10.3892/or.2019.7001.
    PubMed     Abstract available

  81. MA Z, Liu X, Zhang Q, Yu Z, et al
    Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROSmediated PI3K/AKT signaling pathway.
    Oncol Rep. 2019;41:811-818.
    PubMed     Abstract available

    January 2019
  82. FONTES-SOUSA M, Amorim M, Salta S, Palma De Sousa S, et al
    Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).
    Oncol Rep. 2019 Jan 11. doi: 10.3892/or.2019.6967.
    PubMed     Abstract available

  83. WEI CW, Yu YL, Chen YH, Hung YT, et al
    Anticancer effects of methotrexate in combination with alphatocopherol and alphatocopherol succinate on triplenegative breast cancer.
    Oncol Rep. 2019 Jan 9. doi: 10.3892/or.2019.6958.
    PubMed     Abstract available

  84. SCHRODER L, Marahrens P, Koch JG, Heidegger H, et al
    Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF7 and MDA-MB-231 breast carcinoma cells.
    Oncol Rep. 2019;41:387-396.
    PubMed     Abstract available

    December 2018
  85. MA J, Niu W, Wang X, Zhou Y, et al
    Bromodomaincontaining protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2antagonist/killer protein.
    Oncol Rep. 2018 Dec 21. doi: 10.3892/or.2018.6951.
    PubMed     Abstract available

  86. KIM S, You D, Jeong Y, Yu J, et al
    TP53 upregulates alphasmooth muscle actin expression in tamoxifenresistant breast cancer cells.
    Oncol Rep. 2018 Dec 6. doi: 10.3892/or.2018.6910.
    PubMed     Abstract available

  87. HUANG S, Yuan N, Wang G, Wu F, et al
    Cellular communication promotes mammosphere growth and collective invasion through microtubulelike structures and angiogenesis.
    Oncol Rep. 2018;40:3297-3312.
    PubMed     Abstract available

    November 2018
  88. JING X, Liang H, Hao C, Yang X, et al
    Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6887.
    PubMed     Abstract available

  89. YAO R, Wang Y, Han D, Ma Y, et al
    Lysines 207 and 325 methylation of WDR5 catalyzed by SETD6 promotes breast cancer cell proliferation and migration.
    Oncol Rep. 2018;40:3069-3077.
    PubMed     Abstract available

  90. HUANG XJ, Xia Y, He GF, Zheng LL, et al
    MALAT1 promotes angiogenesis of breast cancer.
    Oncol Rep. 2018;40:2683-2689.
    PubMed     Abstract available

  91. HENG ZSL, Lee JY, Subhramanyam CS, Wang C, et al
    The role of 17betaestradiolinduced upregulation of Piwilike 4 in modulating gene expression and motility in breast cancer cells.
    Oncol Rep. 2018;40:2525-2535.
    PubMed     Abstract available

  92. YANG PJ, Hou MF, Tsai EM, Liang SS, et al
    Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain 33 (ADAM33) gene affected by endocrinedisrupting chemicals.
    Oncol Rep. 2018;40:2766-2777.
    PubMed     Abstract available

  93. ZHU L, Li XX, Shi L, Wu J, et al
    Rapamycin enhances the sensitivity of ERpositive breast cancer cells to tamoxifen by upregulating p73 expression.
    Oncol Rep. 2018 Nov 1. doi: 10.3892/or.2018.6842.
    PubMed     Abstract available

  94. KIM MH, Park JW, Lee EJ, Kim S, et al
    C16ceramide and sphingosine 1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.
    Oncol Rep. 2018;40:2977-2987.
    PubMed     Abstract available

    October 2018
  95. XIE WY, He RH, Zhang J, He YJ, et al
    betablockers inhibit the viability of breast cancer cells by regulating the ERK/COX2 signaling pathway and the drug response is affected by ADRB2 singlenucleotide polymorphisms.
    Oncol Rep. 2018 Oct 29. doi: 10.3892/or.2018.6830.
    PubMed     Abstract available

  96. EL-TABBA' RM, Mathew P, Masocha W, Khajah MA, et al
    COL3 enhances the antiproliferative and proapoptotic effects of paclitaxel in breast cancer cells.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6815.
    PubMed     Abstract available

  97. LI W, Yang H, Li X, Han L, et al
    Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
    Oncol Rep. 2018 Oct 18. doi: 10.3892/or.2018.6805.
    PubMed     Abstract available

  98. WANG L, Shi H, Zhang X, Zhang X, et al
    I157172, a novel inhibitor of cystathionine gamma-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.
    Oncol Rep. 2018 Oct 16. doi: 10.3892/or.2018.6798.
    PubMed     Abstract available

  99. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2018 Oct 9. doi: 10.3892/or.2018.6780.
    PubMed     Abstract available

  100. SHETTAR A, Damineni S, Mukherjee G, Kondaiah P, et al
    Gap junction beta2 expression is negatively associated with the estrogen receptor status in breast cancer tissues and is a regulator of breast tumorigenesis.
    Oncol Rep. 2018 Oct 3. doi: 10.3892/or.2018.6764.
    PubMed     Abstract available

  101. ZHU L, Zhou W, Zhu X, Xiang S, et al
    Inhibitor of apoptosis proteinlike protein2: A novel growth accelerator for breast cancer cells.
    Oncol Rep. 2018;40:2047-2055.
    PubMed     Abstract available

  102. JIN ZQ, Hao J, Yang X, He JH, et al
    Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
    Oncol Rep. 2018;40:2127-2136.
    PubMed     Abstract available

  103. ZHUO Y, Li X, Zheng Q, Fan X, et al
    Estrogen enhances tumor growth and angiogenesis indirectly via mediation of bone marrowderived cells as well as directly through stimulation of tumor and endothelial cells.
    Oncol Rep. 2018;40:2147-2156.
    PubMed     Abstract available

  104. NETSIRISAWAN P, Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, et al
    Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.
    Oncol Rep. 2018;40:2193-2205.
    PubMed     Abstract available

  105. ALSAMMAN K, El-Masry OS
    Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Oncol Rep. 2018;40:2157-2162.
    PubMed     Abstract available

  106. SUN X, Zhang H, Zhang Y, Yang Q, et al
    Caspase-dependent mitochondrial apoptotic pathway is involved in astilbin-mediated cytotoxicity in breast carcinoma cells.
    Oncol Rep. 2018;40:2278-2286.
    PubMed     Abstract available

  107. LIAO S, Gan L, Qin W, Liu C, et al
    Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways.
    Oncol Rep. 2018;40:2005-2013.
    PubMed     Abstract available

    September 2018
  108. XIE D, Song H, Wu T, Li D, et al
    MicroRNA424 serves an antioncogenic role by targeting cyclindependent kinase 1 in breast cancer cells.
    Oncol Rep. 2018 Sep 27. doi: 10.3892/or.2018.6741.
    PubMed     Abstract available

  109. CHEN J, Tian W, He H, Chen F, et al
    Downregulation of miR200c3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
    Oncol Rep. 2018 Sep 26. doi: 10.3892/or.2018.6735.
    PubMed     Abstract available

  110. WANG YJ, Zheng LY, Wang ZF, Song R, et al
    Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.
    Oncol Rep. 2018 Sep 21. doi: 10.3892/or.2018.6725.
    PubMed     Abstract available

  111. ZHAO H, Yang Q, Hu Y, Zhang J, et al
    Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triplenegative breast cancer cells.
    Oncol Rep. 2018 Sep 20. doi: 10.3892/or.2018.6716.
    PubMed     Abstract available

  112. KO YS, Jin H, Lee JS, Park SW, et al
    Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells.
    Oncol Rep. 2018 Sep 18. doi: 10.3892/or.2018.6714.
    PubMed     Abstract available

    August 2018
  113. CHEN Y, Wei L, Zhang X, Liu X, et al
    3Bromopyruvate sensitizes human breast cancer cells to TRAILinduced apoptosis via the phosphorylated AMPKmediated upregulation of DR5.
    Oncol Rep. 2018 Aug 14. doi: 10.3892/or.2018.6644.
    PubMed     Abstract available

  114. GUAN J, Zhou Y, Mao F, Lin Y, et al
    MicroRNA320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulinlike growth factor 1 receptor.
    Oncol Rep. 2018;40:849-858.
    PubMed     Abstract available

  115. YU Z, Lou L, Zhao Y
    Fibroblast growth factor 18 promotes the growth, migration and invasion of MDAMB231 cells.
    Oncol Rep. 2018;40:704-714.
    PubMed     Abstract available

    July 2018
  116. TAKEMORI T, Kawamoto T, Ueha T, Toda M, et al
    Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Oncol Rep. 2018 Jul 30. doi: 10.3892/or.2018.6608.
    PubMed     Abstract available

  117. CALAF GM, Ponce-Cusi R, Carrion F
    Curcumin and paclitaxel induce cell death in breast cancer cell lines.
    Oncol Rep. 2018 Jul 26. doi: 10.3892/or.2018.6603.
    PubMed     Abstract available

  118. ZHOU XL, Zeng, Ye YH, Sun SM, et al
    Prognostic values of the inhibitor of DNAbinding family members in breast cancer.
    Oncol Rep. 2018 Jul 23. doi: 10.3892/or.2018.6589.
    PubMed     Abstract available

  119. WANG H, He Z, Xia L, Zhang W, et al
    PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.
    Oncol Rep. 2018 Jul 20. doi: 10.3892/or.2018.6588.
    PubMed     Abstract available

  120. LI S, Dai H, He Y, Peng S, et al
    BMP9 inhibits the growth of breast cancer cells by downregulation of the PI3K/Akt signaling pathway.
    Oncol Rep. 2018 Jul 13. doi: 10.3892/or.2018.6572.
    PubMed     Abstract available

  121. JI Y, Jiang Q, Jian G, Sun H, et al
    Developing a radiosensitivity gene signature for Caucasian patients with breast cancer.
    Oncol Rep. 2018 Jul 12. doi: 10.3892/or.2018.6567.
    PubMed     Abstract available

    June 2018
  122. CANZONERI R, Rabassa ME, Gurruchaga A, Ferretti V, et al
    Alternative splicing variant of RHBDD2 is associated with cell stress response and breast cancer progression.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6489.
    PubMed     Abstract available

  123. ZHAO W, Kuai X, Zhou X, Jia L, et al
    Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6496.
    PubMed     Abstract available

  124. VAKLAVAS C, Zinn KR, Samuel SL, Meng Z, et al
    Translational control of the undifferentiated phenotype in ERpositive breast tumor cells: Cytoplasmic localization of ERalpha and impact of IRES inhibition.
    Oncol Rep. 2018;39:2482-2498.
    PubMed     Abstract available

  125. ZHANG GM, Goyal H, Song LL
    Bioinformatics analysis of differentially expressed miRNA-related mRNAs and their prognostic value in breast carcinoma.
    Oncol Rep. 2018;39:2865-2872.
    PubMed     Abstract available

    May 2018
  126. CHOI JW, Moon BI, Lee JW, Kim HJ, et al
    Use of CA153 for screening breast cancer: An antibodylectin sandwich assay for detecting glycosylation of CA153 in sera.
    Oncol Rep. 2018 May 10. doi: 10.3892/or.2018.6433.
    PubMed     Abstract available

  127. WANG Y, Guo L, Feng L, Zhang W, et al
    Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer.
    Oncol Rep. 2018;39:2147-2159.
    PubMed     Abstract available

  128. XU L, Che X, Wu Y, Song N, et al
    SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Oncol Rep. 2018;39:2315-2323.
    PubMed     Abstract available

  129. NUVOLI S, Galassi S, Gelo I, Rocchitta G, et al
    The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Oncol Rep. 2018;39:2055-2062.
    PubMed     Abstract available

    April 2018
  130. WANG Y, Zhang Z, Wang J
    MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1.
    Oncol Rep. 2018 Apr 20. doi: 10.3892/or.2018.6385.
    PubMed     Abstract available

  131. CALAF GM, Ponce-Cusi R, Abarca-Quinones J
    Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
    Oncol Rep. 2018 Apr 20. doi: 10.3892/or.2018.6386.
    PubMed     Abstract available

  132. WANG X, Qiu H, Tang R, Song H, et al
    miR30a inhibits epithelialmesenchymal transition and metastasis in triplenegative breast cancer by targeting ROR1.
    Oncol Rep. 2018 Apr 18. doi: 10.3892/or.2018.6379.
    PubMed     Abstract available

  133. TOPCUL M, Ceti N IL, Ozbas Turan S, Kolusayin Ozar MO, et al
    In vitro cytotoxic effect of PARP inhibitor alone and in combination with nabpaclitaxel on triplenegative and luminal A breast cancer cells.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6364.
    PubMed     Abstract available

  134. LUO T, Yan Y, He Q, Ma X, et al
    miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE.
    Oncol Rep. 2018 Apr 4. doi: 10.3892/or.2018.6353.
    PubMed     Abstract available

  135. SHEN Y, Zhong J, Liu J, Liu K, et al
    Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-alpha36.
    Oncol Rep. 2018 Apr 2. doi: 10.3892/or.2018.6350.
    PubMed     Abstract available

  136. OH YJ, Park SY, Seo YH
    The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oncol Rep. 2018;39:1775-1782.
    PubMed     Abstract available

    March 2018
  137. LEON-GALICIA I, Diaz-Chavez J, Albino-Sanchez ME, Garcia-Villa E, et al
    Resveratrol decreases Rad51 expression and sensitizes cisplatinresistant MCF7 breast cancer cells.
    Oncol Rep. 2018 Mar 27. doi: 10.3892/or.2018.6336.
    PubMed     Abstract available

  138. LIN CC, Lo MC, Moody RR, Stevers NO, et al
    Doxycycline targets aldehyde dehydrogenasepositive breast cancer stem cells.
    Oncol Rep. 2018 Mar 27. doi: 10.3892/or.2018.6337.
    PubMed     Abstract available

  139. LIU M, Liu H, Chen J
    Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
    Oncol Rep. 2018;39:901-911.
    PubMed     Abstract available

    February 2018
  140. RATHINAVELU A, Kanagasabai T, Dhandayuthapani S, Alhazzani K, et al
    Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models.
    Oncol Rep. 2018 Feb 9. doi: 10.3892/or.2018.6256.
    PubMed     Abstract available

  141. SHENG C, Qiu J, He Z, Wang H, et al
    Suppression of Kpnbeta1 expression inhibits human breast cancer cell proliferation by abrogating nuclear transport of Her2.
    Oncol Rep. 2018;39:554-564.
    PubMed     Abstract available

    January 2018
  142. HU B, Meng X, Zhang Y, Hossain MM, et al
    Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF7 cells in vitro and in vivo and its mechanism of action.
    Oncol Rep. 2018 Jan 26. doi: 10.3892/or.2018.6237.
    PubMed     Abstract available

  143. YIN G, Zeng B, Peng Z, Liu Y, et al
    Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
    Oncol Rep. 2018 Jan 11. doi: 10.3892/or.2018.6212.
    PubMed     Abstract available

  144. WANG YW, Zhang W, Ma R
    Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
    Oncol Rep. 2018 Jan 10. doi: 10.3892/or.2018.6205.
    PubMed     Abstract available

  145. ZHAO M, Wang Y, Du C, Liu Y, et al
    Aspirin and metformin exhibit antitumor activity in murine breast cancer.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6190.
    PubMed     Abstract available

  146. KASORN A, Loison F, Kangsamaksin T, Jongrungruangchok S, et al
    Terrein inhibits migration of human breast cancer cells via inhibition of the Rho and Rac signaling pathways.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6189.
    PubMed     Abstract available

    December 2017
  147. WANG Y, Li L, Wang H, Li J, et al
    Silencing TGIF suppresses migration, invasion and metastasis of MDAMB231 human breast cancer cells.
    Oncol Rep. 2017 Dec 4. doi: 10.3892/or.2017.6133.
    PubMed     Abstract available

    November 2017
  148. LIN SC, Chu PY, Liao WT, Wu MY, et al
    Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6123.
    PubMed     Abstract available

    Anticancer pyridines induce G2/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells.
    Oncol Rep. 2017 Nov 28. doi: 10.3892/or.2017.6116.
    PubMed     Abstract available

  150. SUI Y, Zhang X, Yang H, Wei W, et al
    MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1.
    Oncol Rep. 2017 Nov 27. doi: 10.3892/or.2017.6114.
    PubMed     Abstract available

  151. QIU N, He Y, Zhang S, Hu X, et al
    Cullin 7 is a predictor of poor prognosis in breast cancer patients and is involved in the proliferation and invasion of breast cancer cells by regulating the cell cycle and microtubule stability.
    Oncol Rep. 2017 Nov 21. doi: 10.3892/or.2017.6106.
    PubMed     Abstract available

  152. AOTO K, Mimura K, Okayama H, Saito M, et al
    Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma.
    Oncol Rep. 2017 Nov 14. doi: 10.3892/or.2017.6097.
    PubMed     Abstract available

  153. ZHANG W, Pan Y, Gou P, Zhou C, et al
    Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6094.
    PubMed     Abstract available

  154. QIU Y, Liu Y, Li WH, Zhang HQ, et al
    P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin.
    Oncol Rep. 2017 Nov 7. doi: 10.3892/or.2017.6081.
    PubMed     Abstract available

  155. GONZALEZ-GONZALEZ A, Gonzalez A, Alonso-Gonzalez C, Menendez-Menendez J, et al
    Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in cocultures of human endothelial and breast cancer cells.
    Oncol Rep. 2017 Nov 2. doi: 10.3892/or.2017.6070.
    PubMed     Abstract available

  156. REN P, Ren X, Cheng L, Xu L, et al
    Frankincense, pine needle and geranium essential oils suppress tumor progression through the regulation of the AMPK/mTOR pathway in breast cancer.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6067.
    PubMed     Abstract available

    October 2017
  157. JIANG Y, Ji F, Liu Y, He M, et al
    Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein.
    Oncol Rep. 2017 Oct 16. doi: 10.3892/or.2017.6035.
    PubMed     Abstract available

  158. HOU W, Zhang H, Bai X, Liu X, et al
    Suppressive role of miR-592 in breast cancer by repressing TGF-beta2.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6029.
    PubMed     Abstract available

  159. HE DX, Wu XL, Lu CX, Gu XT, et al
    Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6033.
    PubMed     Abstract available

  160. YANG L, Song Z, Wang X, Yang W, et al
    Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-kappaB/IkappaBalpha pathway.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6024.
    PubMed     Abstract available

  161. HAN Y, Zhang L, Wang W, Li J, et al
    Livin promotes the progression and metastasis of breast cancer through the regulation of epithelialmesenchymal transition via the p38/GSK3beta pathway.
    Oncol Rep. 2017 Oct 10. doi: 10.3892/or.2017.6017.
    PubMed     Abstract available

    September 2017
  162. ZHOU T, Zhang A, Kuang G, Gong X, et al
    Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting beta-catenin signaling.
    Oncol Rep. 2017 Sep 28. doi: 10.3892/or.2017.6011.
    PubMed     Abstract available

  163. ONO H, Iizumi Y, Goi W, Sowa Y, et al
    Ribosomal protein S3 regulates XIAP expression independently of the NF-kappaB pathway in breast cancer cells.
    Oncol Rep. 2017 Sep 27. doi: 10.3892/or.2017.6008.
    PubMed     Abstract available

  164. AN J, Wang L, Zhao Y, Hao Q, et al
    Effects of FSTL1 on cell proliferation in breast cancer cell line MDAMB231 and its brain metastatic variant MDAMB231BR.
    Oncol Rep. 2017 Sep 26. doi: 10.3892/or.2017.6004.
    PubMed     Abstract available

  165. ZHANG Y, Wang DL, Yan HY, Liao JY, et al
    Genome-wide study of ER-regulated lncRNAs shows AP000439.3 may function as a key regulator of cell cycle in breast cancer.
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5975.
    PubMed     Abstract available

  166. TANG CP, Zhou HJ, Qin J, Luo Y, et al
    MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer.
    Oncol Rep. 2017 Sep 19. doi: 10.3892/or.2017.5968.
    PubMed     Abstract available

  167. ZHAO Y, Ge CC, Wang J, Wu XX, et al
    MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing beta-catenin nuclear accumulation.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5955.
    PubMed     Abstract available

    June 2017
  168. XU W, Wu B, Fu L, Chen J, et al
    Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis.
    Oncol Rep. 2017;37:3219-3226.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.